Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PanDox: Feasibility of Enhanced Chemotherapy Delivery to Non-resectable Primary Pancreatic Tumours Using Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Focused Ultrasound

Next Previous
Trial Profile

PanDox: Feasibility of Enhanced Chemotherapy Delivery to Non-resectable Primary Pancreatic Tumours Using Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Focused Ultrasound

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Doxorubicin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Pharmacokinetics
  • Acronyms PanDox

Most Recent Events

  • 03 Apr 2023 Planned End Date changed from 1 Dec 2022 to 30 Mar 2023.
  • 03 Apr 2023 Planned primary completion date changed from 1 May 2022 to 30 Mar 2023.
  • 03 Apr 2023 Planned initiation date changed from 1 May 2021 to 16 Jun 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top